New answers only muddy the water on supplementary protection certificates
By Dr Matthew Royle, Paul England and Julia Bödeker
Just one month after its ruling in GlaxoSmithKline Biologicals SA (C-210/13) on the application of the supplementary protection certificate regulation 469/2009/EC (SPC Regulation) to vaccine adjuvants, the Court of Justice of the European Union (CJEU) delivered three more important rulings on the same regulation on the same day: 12 December 2013. All the rulings follow from referrals made by national courts, seeking clarification of issues that had arisen as a result of the Court of Justice of the European Union’s (CJEU’s) rulings in Neurim Pharmaceuticals (C- 130/11) and Medeva (C-322/10).
The issues raised are acutely important to understanding the circumstances in which a patent can support the valid grant of an SPC for a product and what constitutes a product in the first place. The issues are these: is an adjuvant an active ingredient and therefore capable of constituting a ‘product’ protectable by an SPC (under article 1[b] SPC Regulation); can more than one SPC be granted on the basis of the same ‘basic patent in force’ (under article 3[a] SPC Regulation); and what does it mean to say that a product, or a process for making that product, must be ‘specified’ or ‘identified’ by a basic patent in force in order to be ‘protected by’ that patent (under article 3[a])?
As discussed below, while the answers to these issues have dealt with the particular factual scenarios in which the references were made, they have also muddied the waters considerably for anyone trying to draw out principles that can be applied more generally. This inevitably means that new questions will need to be addressed by the CJEU in due course. Unless, of course, the commission takes Arnold J’s advice and re-casts the SPC Regulation…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
For the tax year from 6 April 2014, the standard lifetime allowance has reduced from £1.5m to £1.25m.
One of the areas highlighted last year by the Regulator was the regulation of workplace DC pension schemes.
Analysis from The Lawyer
As the equity capital markets rocketed back into favour and global M&A saw at least a partial return to form, there have been some rich pickings for The Lawyer’s Corporate Team of the Year award shortlisted firms in 2014.
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world